prikaz prve stranice dokumenta Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment
Access restricted to students and staff of home institution
Scientific paper - Review paper
Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment
Endocrine Oncology and Metabolism, 2 (2016), 3; 174-193. https://doi.org/10.21040/eom/2016.2.3.3
Strinović, Mateja; Kruljac, Ivan; Dabelić, Nina; Nikolić, Marko; Ljubičić, Neven; Filipović Čugura, Jakša; Vazdar, Ljubica; Marić Brozić, Jasmina; Kust, Davor; Petranović Ovčariček, Petra; Gladić Nenadić, Vedrana; Marjan, Domagoj; Ulamec, Monika; Demirović, Alma; Miculinić, Andrija; Vrkljan, Milan More authors...

Citations:
,
Cite this document

Strinović, M., Kruljac, I., Dabelić, N., Nikolić, M., Ljubičić, N., Filipović Čugura, J. ... Vrkljan, M. (2016). Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment. Endocrine Oncology and Metabolism, 2. (3), 174-193. doi: 10.21040/eom/2016.2.3.3

Strinović, Mateja, et al. "Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment." Endocrine Oncology and Metabolism, vol. 2, no. 3, 2016, pp. 174-193. https://doi.org/10.21040/eom/2016.2.3.3

Strinović, Mateja, Ivan Kruljac, Nina Dabelić, Marko Nikolić, Neven Ljubičić, Jakša Filipović Čugura, Ljubica Vazdar, et al. "Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment." Endocrine Oncology and Metabolism 2, no. 3 (2016): 174-193. https://doi.org/10.21040/eom/2016.2.3.3

Strinović, M., et al. (2016) 'Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment', Endocrine Oncology and Metabolism, 2(3), pp. 174-193. doi: 10.21040/eom/2016.2.3.3

Strinović M, Kruljac I, Dabelić N, Nikolić M, Ljubičić N, Filipović Čugura J, and sur.. Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment. Endocrine Oncology and Metabolism [Internet]. 2016 [cited 2025 March 27];2(3):174-193. doi: 10.21040/eom/2016.2.3.3

M. Strinović, et al., "Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment", Endocrine Oncology and Metabolism, vol. 2, no. 3, pp. 174-193, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:475146. [Accessed: 27 March 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Duodenal neuroendocrine tumors (d-NETs): challenges in diagnosis and treatment
AuthorMateja Strinović
AuthorIvan Kruljac
AuthorNina Dabelić
AuthorMarko Nikolić
AuthorNeven Ljubičić
AuthorJakša Filipović Čugura
AuthorLjubica Vazdar
AuthorJasmina Marić Brozić
AuthorDavor Kust
AuthorPetra Petranović Ovčariček
AuthorVedrana Gladić Nenadić
AuthorDomagoj Marjan
AuthorMonika Ulamec
AuthorAlma Demirović
AuthorAndrija Miculinić
AuthorMilan Vrkljan
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Duodenal neuroendocrine tumors (d-NETs) represent 2% of all gastroenteropancreatic neuroendocrine neoplasms. Approximately 40 to 60% of patients at the time of diagnosis have metastases to regional lymph nodes and 10% have liver metastases. D-NETs are mostly incidentally discovered during upper gastrointestinal endoscopy as solitary lesions confined to the mucosa and submucosa. The majority of d-NETs are non-functional, but 10% are gastrinomas and less than 4% present with typical carcinoid... More syndrome. Measurement of serum gastrin and chromogranin A and screening for the MEN-1 syndrome is mandatory in all patients, while 5-HIAA should be measured only in case of typical symptoms. Magnetic resonance imaging (MRI) may be used to assess tumor spread and to detect primary tumor. Endoscopic ultrasound should be routinely used only for patients who are candidates for endoscopic treatment. Approximately 50% of patients have positive findings on somatostatin receptor scintigraphy (SRS), which should be used only in patients with metastatic disease. Treatment of d-NETs is controversial. Further studies are mandatory in order to detect patients who would benefit from radical surgery, which is associated with high mortality and morbidity rates. Current knowledge suggests that all tumors larger than 20 mm in diameter, sporadic gastrinomas and all periampulary dNETs must undergo radical surgery. Endoscopic mucosal resection is treatment of choice for G1 d-NETs smaller than 20 mm confined to submucosa. Transduodenal surgical resection may be used for patients with d-NETs invading muscularis propria. Additional surgical interventions are recommended after endoscopic treatment in case of G1 or G2 d-NETs with positive margins, G2 or G3 histological grading, invasion into muscular layer or in case of lymphovascular invasion. In case of metastatic disease, cytoreductive surgery should be considered as it improves overall 5-year survival rates. Somatostatin analogs may be used for G1 and G2 tumors, while cisplatin and etopozide should be used for G3 d-NETs. Everolimus may be effective for patients with G2 d-NETs. Peptide receptor radionuclide therapy may be used for patients with positive SRS and progressive disease. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleEndocrine Oncology and Metabolism
Numberingvol. 2, no. 3, pp. 174-193
p-ISSN1849-8922
e-ISSN1849-9031
DOIhttps://doi.org/10.21040/eom/2016.2.3.3
URN:NBNurn:nbn:hr:220:475146
Publication2016
Document URLhttp://eom.hdeo.eu/wp-content/uploads/2016/10/vol2-iss3-3Strinovic.pdf
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2025-03-17 13:28:21
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.